CD14 and cancer: For 260C/T polymorphism, overall, no significant associations between the CD14 -260C/T polymorphism and cancer risk were found (dominant model: OR = 0.89, 95%CI: 0.73–1.07; recessive model: OR = 1.08, 95%CI: 0.93–1.25; CT vs. CC: OR = 0.85, 95%CI: 0.70–1.03; TT vs. CC: OR = 0.95, 95%CI: 0.76–1.19) (Table 2, Figure 2A).